A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.
Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to interleukin-1beta.
Lorbrena is a third generation ALK tyrosine kinase inhibitor.
Although patient-reported outcomes measures were similar with lorlatinib and crizotinib in non-small cell lung cancer, more patients reported improvement in symptoms with lorlatinib.
The addition of durvalumab after chemoradiotherapy for treatment of stage III NSCLC was cost-effective compared with chemoradiotherapy alone.
The aim of the phase 3 J-AXEL trial was to confirm nab-paclitaxel’s noninferiority to docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).
The approval was based on data from the multicenter, single-arm, open-label, multicohort phase 2 VISION study.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
This study characterizes the effect of corticosteroid use for immune-related adverse event (irAE) management on survival in patients with non-small cell lung cancer who received immune checkpoint inhibitor therapy.
The Fleischner Society published a position paper on the role of chest computed tomography diagnosis of drug-related pneumonitis in patients treated with molecular targeting therapies and immune checkpoint inhibitors.
